TY - JOUR
T1 - Predictors of distant metastases in triple-negative breast cancer without pathologic complete response after neoadjuvant chemotherapy
AU - Kennedy, William R.
AU - Tricarico, Christopher
AU - Gabani, Prashant
AU - Weiner, Ashley A.
AU - Altman, Michael B.
AU - Ochoa, Laura L.
AU - Thomas, Maria A.
AU - Margenthaler, Julie A.
AU - Sanati, Souzan
AU - Peterson, Lindsay L.
AU - Ma, Cynthia X.
AU - Ademuyiwa, Foluso O.
AU - Zoberi, Imran
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network
PY - 2020
Y1 - 2020
N2 - Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) predicts decreased distant metastasis. However, most patients do not experience pCR, and other risk factors for distant metastasis after NAC are poorly characterized. This study investigated factors predictive of distant metastasis in TNBC without pCR after NAC. Methods: Women with TNBC treated with NAC, surgery, and radiation therapy in 2000 through 2013 were reviewed. Freedom from distant metastasis (FFDM) was compared between patients with and without pCR using the Kaplan-Meier method. In patients without pCR, univariate and multivariable Cox analyses were used to determine factors predictive of distant metastasis. Results: We identified 153 patients with median follow-up of 4.0 years (range, 0.5–14.0 years). After NAC, 108 had residual disease (pCR, 29%). Five-year FFDM was 98% and 55% in patients with and without pCR, respectively (P,.001). Factors independently predicting FFDM in patients without pCR were pathologic nodal positivity (hazard ratio, 3.08; 95% CI, 1.54–6.14; P5.001) and lymphovascular space invasion (hazard ratio, 1.91; 95% CI, 1.07–3.43; P5.030). Patients with a greater number of factors had worse FFDM; 5-year FFDM was 76.5% for patients with no factors (n538) versus 54.9% and 27.5% for patients with 1 (n544) and 2 factors (n526), respectively (P,.001). Conclusions: Lack of pCR after NAC resulted in worse overall survival and FFDM, despite trimodality therapy. In patients with residual disease after NAC, pathologic lymph node positivity and lymphovascular space invasion predicted worse FFDM.
AB - Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) predicts decreased distant metastasis. However, most patients do not experience pCR, and other risk factors for distant metastasis after NAC are poorly characterized. This study investigated factors predictive of distant metastasis in TNBC without pCR after NAC. Methods: Women with TNBC treated with NAC, surgery, and radiation therapy in 2000 through 2013 were reviewed. Freedom from distant metastasis (FFDM) was compared between patients with and without pCR using the Kaplan-Meier method. In patients without pCR, univariate and multivariable Cox analyses were used to determine factors predictive of distant metastasis. Results: We identified 153 patients with median follow-up of 4.0 years (range, 0.5–14.0 years). After NAC, 108 had residual disease (pCR, 29%). Five-year FFDM was 98% and 55% in patients with and without pCR, respectively (P,.001). Factors independently predicting FFDM in patients without pCR were pathologic nodal positivity (hazard ratio, 3.08; 95% CI, 1.54–6.14; P5.001) and lymphovascular space invasion (hazard ratio, 1.91; 95% CI, 1.07–3.43; P5.030). Patients with a greater number of factors had worse FFDM; 5-year FFDM was 76.5% for patients with no factors (n538) versus 54.9% and 27.5% for patients with 1 (n544) and 2 factors (n526), respectively (P,.001). Conclusions: Lack of pCR after NAC resulted in worse overall survival and FFDM, despite trimodality therapy. In patients with residual disease after NAC, pathologic lymph node positivity and lymphovascular space invasion predicted worse FFDM.
UR - http://www.scopus.com/inward/record.url?scp=85081346959&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2019.7366
DO - 10.6004/jnccn.2019.7366
M3 - Article
C2 - 32135512
AN - SCOPUS:85081346959
SN - 1540-1405
VL - 18
SP - 288
EP - 296
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 3
ER -